Tecentriq

Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
BioSpace
Roche
Genentech
Tecentriq
triple negative breast cancer
clinical trials
Celgene
Abraxane
Flag link:
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Endpoints
Roche
Avastin
Tecentriq
metastatic hepatocellular carcinoma
liver cancer
FDA
Flag link:
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
Pharmaceutical Business Review
Genentech
Roche
Tecentriq
FDA
metastatic non-small cell lung cancer
Flag link:
Roche’s TIGIT drug shows promise in untreated lung cancer
Roche’s TIGIT drug shows promise in untreated lung cancer
Pharmaforum
Roche
ASCO 2020
tiragolumab
Tecentriq
metastatic non-small cell lung cancer
Flag link:
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
Fierce Pharma
Roche
Tecentriq
Cotellic
Zelboraf
melanoma
AACR
Flag link:
Kahr raises $18M to test CD47 drug with Roche's Tecentriq
Kahr raises $18M to test CD47 drug with Roche's Tecentriq
Fierce Biotech
Kahr Medical
anti-CD47
Roche
Tecentriq
Flag link:
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Motley Fool
Roche
FDA
priority review
Tecentriq
non-squamous non-small cell lung cancer
non-small cell lung cancer
Flag link:
Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC
Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC
Pharmaceutical Business Review
Roche
China
NMPA
Tecentriq
extensive-stage small cell lung cancer
Flag link:
Perioperative use proves elusive for Tecentriq
Perioperative use proves elusive for Tecentriq
EP Vantage
Roche
Tecentriq
Flag link:
Roche's Tecentriq fails trial in form of urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Flag link:
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Fierce Pharma
Roche
Tecentriq
NICE
UK
Small-Cell Lung Cancer
Flag link:
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
ESMO
Roche
Tecentriq
non-small cell lung cancer
Flag link:
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
Fierce Pharma
Merck
Ketyruda
Roche
Tecentriq
immuno-oncology
SABCS
triple-negative breast cancer
Flag link:
Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC
Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC
Pharmaceutical Business Review
Roche
Tecentriq
metastatic non-squamous non-small cell lung cancer
FDA
Flag link:
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Endpoints
Roche
Tecentriq
Avastin
liver cancer
China
Bayer
Nexavar
clinical trials
Flag link:
Roche's Tecentriq scores a first-in-class double win in new liver cancer patients
Roche's Tecentriq scores a first-in-class double win in new liver cancer patients
Fierce Pharma
Roche
liver cancer
Tecentriq
immuno-oncology
Avastin
Nexavar
Flag link:
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
Pharmaceutical Business Review
Roche
Tecentriq
clinical trials
non-small cell lung cancer
Flag link:
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
EP Vantage
ESMO
Keytruda
Tecentriq
Merck
Roche
Flag link:

Pages